Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.

Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG.

PLoS Pathog. 2013 Jan;9(1):e1003125. doi: 10.1371/journal.ppat.1003125.

2.

The hepatitis B virus ribonuclease H as a drug target.

Tavis JE, Lomonosova E.

Antiviral Res. 2015 Jun;118:132-8. doi: 10.1016/j.antiviral.2015.04.002. Review.

3.

Update on hepatitis B virus infection.

You CR, Lee SW, Jang JW, Yoon SK.

World J Gastroenterol. 2014 Oct 7;20(37):13293-305. doi: 10.3748/wjg.v20.i37.13293. Review.

4.

Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.

Clark DN, Hu J.

Antiviral Res. 2015 Nov;123:132-7. doi: 10.1016/j.antiviral.2015.09.011. Review.

5.

On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.

Chien RN.

J Gastroenterol Hepatol. 2010 May;25(5):852-7. doi: 10.1111/j.1440-1746.2010.06271.x. Review.

PMID:
20546437
6.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists..

Neth J Med. 2008 Jul-Aug;66(7):292-306. Review.

7.

Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B.

Yuan HJ, Lee WM.

Curr Mol Med. 2007 Mar;7(2):185-97. Review.

PMID:
17346170
8.

Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.

Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S.

Curr Pharm Des. 2002;8(8):595-614. Review.

PMID:
11945161
9.

Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.

Glebe D, Geipel A.

Intervirology. 2014;57(3-4):225-31. doi: 10.1159/000360950. Review.

PMID:
25034492
10.

Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.

Seo Y, Yano Y.

World J Gastroenterol. 2014 Oct 7;20(37):13284-92. doi: 10.3748/wjg.v20.i37.13284. Review.

11.

HIV-1 integrase and RNase H activities as therapeutic targets.

Andréola ML, De Soultrait VR, Fournier M, Parissi V, Desjobert C, Litvak S.

Expert Opin Ther Targets. 2002 Aug;6(4):433-46. Review.

PMID:
12223059
12.

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.

Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J.

Ann Hepatol. 2013 May-Jun;12(3):364-72. Review.

13.

Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.

Chien RN, Liaw YF.

Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. doi: 10.1016/j.bpg.2008.11.003. Review.

PMID:
19187868
14.

Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.

Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H.

World J Gastroenterol. 2012 Dec 28;18(48):7149-57. doi: 10.3748/wjg.v18.i48.7149. Review.

15.

Hepatitis B virus therapy: What's the future holding for us?

Manzoor S, Saalim M, Imran M, Resham S, Ashraf J.

World J Gastroenterol. 2015 Nov 28;21(44):12558-75. doi: 10.3748/wjg.v21.i44.12558. Review.

16.

Perspectives for the treatment of hepatitis B virus infections.

De Clercq E.

Int J Antimicrob Agents. 1999 Jul;12(2):81-95. Review.

PMID:
10418752
17.

Drug resistance in antiviral therapy.

Locarnini S, Bowden S.

Clin Liver Dis. 2010 Aug;14(3):439-59. doi: 10.1016/j.cld.2010.05.004. Review.

PMID:
20638024
18.

Hepatitis B virus: from diagnosis to treatment.

Dény P, Zoulim F.

Pathol Biol (Paris). 2010 Aug;58(4):245-53. doi: 10.1016/j.patbio.2010.05.002. Review.

PMID:
20580167
19.

Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.

Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N.

Expert Opin Pharmacother. 2014 Jul;15(10):1337-49. doi: 10.1517/14656566.2014.913571. Review.

PMID:
24773464
20.

A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery.

Morgnanesi D, Heinrichs EJ, Mele AR, Wilkinson S, Zhou S, Kulp JL 3rd.

Antiviral Res. 2015 Nov;123:204-15. doi: 10.1016/j.antiviral.2015.10.014. Review.

PMID:
26477294
Items per page

Supplemental Content

Support Center